Your session is about to expire
← Back to Search
KRT-232 + TKI for Chronic Myeloid Leukemia
Study Summary
This trial is looking at a new drug, KRT-232, to see if it is effective in treating patients with a certain type of leukemia who have not responded well to other treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer has the T315I mutation.I cannot tolerate my current TKI medication.I have had a cancer treatment that didn't work or I couldn't tolerate it.I am 18 years old or older.I can care for myself and am up and about more than 50% of my waking hours.My blood, liver, and kidney functions are all within normal ranges.I have chronic myeloid leukemia in the accelerated phase and it's Ph+ and BCR-ABL+.My leukemia is TP53 wild type, Ph+, and BCR-ABL+.My leukemia is Ph+ and BCR-ABL+.I have previously been treated with MDM2 antagonist therapies.My leukemia is TP53 wild-type, Ph+, and BCR-ABL+.
- Group 1: Part 1, KRT-232 combined with TKI (Dasatinib or Nilotinib) in patients with CML-CP
- Group 2: Part 2, Arm A (KRT-232 combined with Dasatinib in patients with CML-CP)
- Group 3: Part 2, Arm B (KRT-232 combined with Nilotinib in patients with CML-CP)
- Group 4: Part 2, Arm C (KRT-232 combined with Dasatinib or Nilotinib in patients with CML-AP)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the primary indication of KRT-232?
"KRT-232 is a medication used to treat various cancers like myeloid leukemia, gastrointestinal stromal tumors, and leukemia."
Are there any other instances where KRT-232 has been explored?
"KRT-232 was first researched in 2004 at Bronson Battle Creek. As of now, there have been a total of 216 completed studies. Out of these, 102 are ongoing, with a majority of them taking place in Toronto, Ontario."
What goals is this experiment looking to achieve?
"The primary focus of this 28 day clinical trial is to investigate the rate of Major hematological response (MaHR) in Part 2, Arm C. Additionally, the study will collect data on Progression-free survival (PFS), Overall survival (OS), and MCyR rate in order to understand the secondary outcomes of the trial."
How many research centers are conducting this trial?
"There are a total of 9 clinical trial sites for this research project. The primary locations are Princess Margaret Cancer Center in Toronto, Georgia Cancer Center at Augusta University, and Texas Oncology- Sammons CC at Baylor. The other 6 sites are located across the United States."
How many individuals are chosen to participate in this research?
"That is correct. The clinical trial in question, as indicated by clinicaltrials.gov, is still recruiting patients. This specific trial was initially posted on May 7th, 2021 and was last updated on March 4th, 2022. The trial needs a total of 109 patients, which will be drawn from 6 different sites."
Are there currently any open spots in this clinical trial?
"Yes, the information on clinicaltrials.gov point out that this clinical trial is currently searching for participants. The clinical trial was originally posted on 5/7/2021 and was most recently edited on 3/4/2022. The trial is admitting 109 participants between 6 sites."
Share this study with friends
Copy Link
Messenger